대한종양외과학회지 (Korean Journal of Clinical Oncology)

  • 제14권2호
  • /
  • Pages.89-94
  • /
  • 2018
  • /
  • 1738-8082(pISSN)
  • /
  • 2288-4084(eISSN)
대한종양외과학회 (Korean Society of Surgical Oncology)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathologic correlation with MUC expression in advanced gastric cancer

  • Kim, Kwang (Department of Surgery, Seoul Paik Hospital, Inje University College of Medicine) ;
  • Choi, Kyeong Woon (Department of Surgery, Seoul Paik Hospital, Inje University College of Medicine) ;
  • Lee, Woo Yong (Department of Surgery, Seoul Paik Hospital, Inje University College of Medicine)
  • 투고 : 2018.06.12
  • 심사 : 2018.10.15
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To investigate the relationship between MUC expression and clinicopathologic factors in advanced gastric cancer. Methods: A total of 237 tumor specimens were assessed for MUC expression by immunohistochemistry. The clinicopathologic factors were investigated with MUC1, MUC2, MUC5AC, and MUC6. Results: MUC1, MUC2, MUC5AC, and MUC6 expression was identified in 148 of 237 (62.4%), 141 of 237 (59.5%), 186 of 237 (78.5%), and 146 of 237 (61.6%) specimens, respectively. MUC1 expression was correlated with age, human epidermal growth factor receptor 2 (HER2) status, lymphatic invasion, Lauren classification and histology. Further multivariate logistic regression analysis revealed a significant correlation between MUC1expression and lymphatic invasion, diffuse type of Lauren classification. MUC5AC expression was correlated with HER2 status, Lauren classification and histology. Further multivariate logistic regression analysis revealed a significant correlation between MUC5AC expression and HER2 status, diffuse and mixed type of Lauren classification. MUC2 and MUC6 expression were not correlated with clinicopathologic factors. The patients of MUC1 expression had poorer survival than those without MUC1 expression, but MUC2, MUC5AC or MUC6 were not related to survival. In an additional multivariate analysis that used the Cox proportional hazards model, MUC1 expression was not significantly correlated with patient survival independent of age, N-stage, and venous invasion. Conclusion: When each of these four MUCs expression is evaluated, in light of clinicopathologic factors, MUC1 expression may be considered as a prognostic factor in patients with advanced gastric cancer. Therefore, careful follow-up may be necessary because the prognosis is poor when MUC1 expression is present.

키워드

참고문헌

  1. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005;22:565-73. https://doi.org/10.1007/s10585-005-5376-z
  2. Kim DH, Shin N, Kim GH, Song GA, Jeon TY, Kim DH, et al. Mucin expression in gastric cancer: reappraisal of its clinicopathologic and prognostic significance. Arch Pathol Lab Med 2013;137:1047-53. https://doi.org/10.5858/arpa.2012-0193-OA
  3. De Bolos C, Garrido M, Real FX. MUC6 apomucin shows a distinct normal tissue distribution that correlates with Lewis antigen expression in the human stomach. Gastroenterology 1995;109:723-34. https://doi.org/10.1016/0016-5085(95)90379-8
  4. Carrato C, Balague C, de Bolos C, Gonzalez E, Gambus G, Planas J, et al. Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology 1994;107:160-72. https://doi.org/10.1016/0016-5085(94)90073-6
  5. Reis CA, David L, Nielsen PA, Clausen H, Mirgorodskaya K, Roepstorff P, et al. Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int J Cancer 1997;74:112-21. https://doi.org/10.1002/(SICI)1097-0215(19970220)74:1<112::AID-IJC19>3.0.CO;2-H
  6. Babu SD, Jayanthi V, Devaraj N, Reis CA, Devaraj H. Expression profile of mucins (MUC2, MUC5AC and MUC6) in Helicobacter pylori infected pre-neoplastic and neoplastic human gastric epithelium. Mol Cancer 2006;5:10. https://doi.org/10.1186/1476-4598-5-10
  7. Pinho SS, Carvalho S, Marcos-Pinto R, Magalhaes A, Oliveira C, Gu J, et al. Gastric cancer: adding glycosylation to the equation. Trends Mol Med 2013;19:664-76. https://doi.org/10.1016/j.molmed.2013.07.003
  8. Ilhan O, Han U, Onal B, Celik SY. Prognostic significance of MUC1, MUC2 and MUC5AC expressions in gastric carcinoma. Turk J Gastroenterol 2010;21:345-52. https://doi.org/10.4318/tjg.2010.0119
  9. Zhang HK, Zhang QM, Zhao TH, Li YY, Yi YF. Expression of mucins and E-cadherin in gastric carcinoma and their clinical significance. World J Gastroenterol 2004;10:3044-7. https://doi.org/10.3748/wjg.v10.i20.3044
  10. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer 2001;92:1427-34. https://doi.org/10.1002/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L
  11. Wang XT, Kong FB, Mai W, Li L, Pang LM. MUC1 Immunohistochemical expression as a prognostic factor in gastric cancer: meta-analysis. Dis Markers 2016;2016:9421571.
  12. Pillai K, Pourgholami MH, Chua TC, Morris DL. MUC1 as a potential target in anticancer therapies. Am J Clin Oncol 2015;38:108-18. https://doi.org/10.1097/COC.0b013e31828f5a07
  13. Terada T. An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum. II. Expression of MUC1, MUC2, MUC5AC, and MUC6 in normal mucosa and in 42 cases. Int J Clin Exp Pathol 2013;6:613-21.
  14. Xiao LJ, Zhao S, Zhao EH, Zheng X, Gou WF, Xing YN, et al. Clinicopathological and prognostic significance of MUC-2, MUC-4 and MUC-5AC expression in japanese gastric carcinomas. Asian Pac J Cancer Prev 2012;13:6447-53. https://doi.org/10.7314/APJCP.2012.13.12.6447
  15. Wang JY, Chang CT, Hsieh JS, Lee LW, Huang TJ, Chai CY, et al. Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas. J Surg Oncol 2003;83:253-60. https://doi.org/10.1002/jso.10222